Immunocord

Graft Engineering of Cord Blood for Enhanced Adoptive Immunotherapy Against Solid Tumors

Health Tech & Life Sciences
Stealth Mode
Pre-Funding Ramat HaSharon, Israel Founded 2016
LinkedIn
Last updated 2026-06-18
Total raised
Stage
Pre-Funding
Founded
2016
Headcount
6
HQ
Ramat HaSharon, Israel
Sector
Health Tech & Life Sciences

About

Immunocord has developed a solution for Graft Engineering of Cord Blood for Enhanced Adoptive Immunotherapy against Solid Tumors.

Q&A

What is Immunocord's primary focus?
Immunocord focuses on Graft Engineering of Cord Blood for Enhanced Adoptive Immunotherapy Against Solid Tumors.
When was Immunocord founded?
Immunocord was founded in February 2016.
What is Immunocord's current operational status?
Immunocord is currently inactive, as of May 2018.
Where is Immunocord headquartered?
Immunocord is headquartered in Ramat HaSharon, Center District, Israel.
How many employees does Immunocord have?
Immunocord has 1-10 employees.
Who is the founder and CEO of Immunocord?
Amnon Pelz is the Founder & CEO of Immunocord.
What is Immunocord's primary sector classification?
Immunocord's primary sector is Health Tech & Life Sciences.
What is Immunocord's current funding stage?
Immunocord is in the Pre-Funding stage.

Team · 1

Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical Devices
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Tags

medical-technologiesimmunotherapyoncologycancerimmunologystealthmode
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)